Isolation and Identification of Multi-Drug Resistant (MDR) Pathogens from Patients with Urinary Tract Infection (UTI) in Dhaka City, Bangladesh

ISSN: 0973-7510

E-ISSN: 2581-690X

Research Article | Open Access

Fatema Khatun¹, Naresh Kumar¹ , Khushboo², Maruf Abony³and Suvamoy Datta⁴

¹Department of Life Sciences, RIMT University, Mandi Gobingarh-147 301, Punjab, India.

²Department of Biosciences, Chandigarh University, Mohali-140 413, Punjab, India.

³Department of Microbiology, Primeasia University, 12 Banani, Dhaka-1213, Bangladesh.

⁴Department of Microbiology, School of Science, Primeasia University, 12 Banani, Dhaka-1213, Bangladesh.

Article Number: 7672 | © The Author(s). 2022

J Pure Appl Microbiol. 2022;16(3):2028-2034. https://doi.org/10.22207/JPAM.16.3.55

Received: 10 March 2022 | Accepted: 14 June 2022 | Published online: 19 August 2022

Issue online: September 2022

Read the full text ❯

Abstract

Urinary tract infection (UTI) is the leading cause of death among patients and majority of people visiting the hospital worldwide. In the current quantitative study, urine samples were obtained using sterile method and 100 isolates, including 60 Escherichia coli, 28 Klebsiella sp., and 12 Proteus sp., were investigated in a laboratory. Current study showed that E. coli 60/100 (60%) was the most common cause of UTI followed by Klebsiella sp. 28/100 (28%) and Proteus sp. 12/100 (12%). Cefotaxime (86.67% sensitive) was found to be the best drug for treating infections with E. coli, ceftazidime (100% sensitive) for infections with Klebsiella sp., and imipenem and levofloxacin (100% sensitive) for infections with Proteus sp. Overall, 51% of the isolated strains showed high multidrug resistance (MDR). Because of the alarming increase in extensively drug-resistant and MDR uropathogens, which is a concern in public health, the rational use of antimicrobial therapy should be implemented.

Keywords

UTI, MDR, Uropathogenic, E.coli, Dhaka

Download PDF

Article Metrics

Article View: 557

JPAM.16.3.55 (838 downloads)

Share This Article

© The Author(s) 2022. Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License which permits unrestricted use, sharing, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.